ATE401314T1 - Benzodiazepin-derivate als gamma-secretase inhibitoren - Google Patents

Benzodiazepin-derivate als gamma-secretase inhibitoren

Info

Publication number
ATE401314T1
ATE401314T1 AT01972352T AT01972352T ATE401314T1 AT E401314 T1 ATE401314 T1 AT E401314T1 AT 01972352 T AT01972352 T AT 01972352T AT 01972352 T AT01972352 T AT 01972352T AT E401314 T1 ATE401314 T1 AT E401314T1
Authority
AT
Austria
Prior art keywords
gamma
secretase inhibitors
benzodiazepine derivatives
compounds
benzodiazepine
Prior art date
Application number
AT01972352T
Other languages
English (en)
Inventor
Ian Churcher
Alan Nadin
Andrew Owens
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of ATE401314T1 publication Critical patent/ATE401314T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
AT01972352T 2000-10-13 2001-10-08 Benzodiazepin-derivate als gamma-secretase inhibitoren ATE401314T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0025173.6A GB0025173D0 (en) 2000-10-13 2000-10-13 Therapeutic agents

Publications (1)

Publication Number Publication Date
ATE401314T1 true ATE401314T1 (de) 2008-08-15

Family

ID=9901256

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01972352T ATE401314T1 (de) 2000-10-13 2001-10-08 Benzodiazepin-derivate als gamma-secretase inhibitoren

Country Status (9)

Country Link
US (1) US6995155B2 (de)
EP (1) EP1326849B1 (de)
JP (1) JP2004511474A (de)
AT (1) ATE401314T1 (de)
AU (1) AU2001292126A1 (de)
CA (1) CA2424812A1 (de)
DE (1) DE60134874D1 (de)
GB (1) GB0025173D0 (de)
WO (1) WO2002030912A1 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001125908A (ja) * 1999-10-26 2001-05-11 Sony Corp 入力装置および方法
GB0012671D0 (en) * 2000-05-24 2000-07-19 Merck Sharp & Dohme Therapeutic agents
JP2004508090A (ja) * 2000-09-08 2004-03-18 コールマン ジェイムス イー 外科用ステープル
US7060698B2 (en) * 2003-05-19 2006-06-13 Hoffmann-La Roche Inc. Benzoxazepinone derivatives
US20070293482A1 (en) * 2004-03-19 2007-12-20 Novartis Pharmaceuticals Corporation Process for Preparing Benzodiazepines
US20060084672A1 (en) * 2004-10-20 2006-04-20 The Hospital For Sick Children Method for modification of y-secretase activity through inhibition of Fkbp13
ATE550019T1 (de) 2005-05-17 2012-04-15 Merck Sharp & Dohme Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
WO2007103114A2 (en) * 2006-03-07 2007-09-13 The Brigham & Women's Hospital, Inc. Notch inhibition in the treatment or prevention of atherosclerosis
US9567396B2 (en) 2006-03-07 2017-02-14 Evonik Degussa Gmbh Notch inhibition in the prevention of vein graft failure
CA2676715A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
CN101945853B (zh) 2007-12-21 2014-08-20 配体药物公司 选择性雄激素受体调节剂(sarm)及其应用
WO2009128057A2 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
EP2413932A4 (de) 2009-04-01 2012-09-19 Merck Sharp & Dohme Hemmer der akt-aktivität
US20120129189A1 (en) * 2009-07-17 2012-05-24 Chulan Kwon Methods of Controlling Cell Proliferation
CA2777043C (en) 2009-10-14 2015-12-15 Schering Corporation Substituted piperidines that increase p53 activity and the uses thereof
EP2493497A4 (de) 2009-11-01 2013-07-24 Brigham & Womens Hospital Notch-hemmung bei der behandlung und prophylaxe von adipositas und dem stoffwechselsyndrom
EP2584903B1 (de) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Neue heterozyklische verbindungen als erk-hemmer
CN103068980B (zh) 2010-08-02 2017-04-05 瑟纳治疗公司 使用短干扰核酸(siNA)的RNA干扰介导的联蛋白(钙粘蛋白关联蛋白质),β1(CTNNB1)基因表达的抑制
RU2745848C2 (ru) 2010-08-17 2021-04-01 Сирна Терапьютикс, Инк. ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
EP2613782B1 (de) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazolderivate als erk-hemmer
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
WO2013059302A1 (en) 2011-10-17 2013-04-25 Nationwide Children's Hospital, Inc. Products and methods for aortic abdominal aneurysm
EP2770987B1 (de) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Neue verbindungen als erk-hemmer
EP3919620A1 (de) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Zusammensetzungen mit kurzer interferierender nukleinsäure (sina)
CA2882950A1 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
SMT201700595T1 (it) 2012-11-28 2018-03-08 Merck Sharp & Dohme Composizioni e metodi per trattare il cancro
WO2014096212A1 (en) * 2012-12-20 2014-06-26 Janssen Pharmaceutica Nv NOVEL TRICYCLIC 3,4-DIHYDRO-2H-PYRIDO[1,2-α]PYRAZINE-1,6-DIONE DERIVATIVES AS GAMMA SECRETASE MODULATORS
WO2014100065A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
KR102171710B1 (ko) 2013-01-17 2020-10-30 얀센 파마슈티카 엔.브이. 감마 세크레타제 조절 인자로서의 신규 치환 피리도-피페라지논 유도체
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
US10562897B2 (en) 2014-01-16 2020-02-18 Janssen Pharmaceutica Nv Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
EP3613418A1 (de) 2014-01-17 2020-02-26 Ligand Pharmaceuticals, Inc. Verfahren und zusammensetzungen zur modulierung von hormonspiegeln
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
WO2019094312A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3706742B1 (de) 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Prmt5-inhibitoren
EP3793563A4 (de) * 2018-05-15 2022-02-23 Bristol-Myers Squibb Company Zusammensetzungen mit bisfluoroalkyl-1,4-benzodiazepinonverbindungen und verwendungsverfahren davon
WO2020016377A1 (en) 2018-07-19 2020-01-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination for treating cancer
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
CA3108388A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833667B1 (de) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5-inhibitoren
WO2020033285A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
AU2020257397B2 (en) 2019-04-19 2026-02-26 Ligand Pharmaceuticals Inc. Crystalline forms and methods of producing crystalline forms of a compound
EP4076459B1 (de) 2019-12-17 2026-04-29 Merck Sharp & Dohme LLC Prmt5-inhibitoren
ES3022307T3 (en) 2019-12-17 2025-05-28 Merck Sharp & Dohme Llc Prmt5 inhibitors
EP4076460B1 (de) 2019-12-17 2026-01-21 Merck Sharp & Dohme LLC 1,4-dihydro-2h-spiro[isoquinoline-3,4'-piperidin]-derivate als prmt5 inhibitoren zur behandlung von krebs
ES3074517T3 (en) 2019-12-17 2026-07-21 Merck Sharp & Dohme Llc 4-(3,4-dihydroisoquinolin-2(1h)-yl)-3-hydroxypiperidine derivatives as prmt5 inhibitors for the treatment of cancer and sickle cell disease
EP4244391A1 (de) 2020-11-16 2023-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren und zusammensetzungen zur vorhersage und behandlung von uvealem melanom
CN120225528A (zh) 2022-09-02 2025-06-27 默沙东有限责任公司 依喜替康衍生的拓扑异构酶-1抑制剂药物组合物及其用途
KR20250079227A (ko) 2022-10-25 2025-06-04 머크 샤프 앤드 돔 엘엘씨 엑사테칸-유래 adc 링커-페이로드, 제약 조성물, 및 그의 용도
KR20250116773A (ko) 2022-12-14 2025-08-01 머크 샤프 앤드 돔 엘엘씨 아우리스타틴 링커-페이로드, 제약 조성물, 및 그의 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5426185A (en) 1993-11-22 1995-06-20 Merck & Co., Inc. Antiarrhythmic benzodiazepines
ZA9711537B (en) 1996-12-23 1998-06-25 Athena Neurosciences Inc Eli L Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting ß-amyloid peptide release and/or its synthesis by use of such compounds.
FR2782997A1 (fr) 1998-09-08 2000-03-10 Hoechst Marion Roussel Inc Nouveaux derives de la benzodiazepinone, procede de preparation et intermediaires de ce procede, application a titre de medicaments et compositions pharmaceutiques les renfermant
CN1636011A (zh) 1998-12-24 2005-07-06 杜邦药品公司 作为Aβ蛋白产生抑制剂的琥珀酰氨基苯并二氮杂䓬
GB0012671D0 (en) * 2000-05-24 2000-07-19 Merck Sharp & Dohme Therapeutic agents

Also Published As

Publication number Publication date
US6995155B2 (en) 2006-02-07
JP2004511474A (ja) 2004-04-15
DE60134874D1 (de) 2008-08-28
EP1326849A1 (de) 2003-07-16
AU2001292126A1 (en) 2002-04-22
US20040024203A1 (en) 2004-02-05
EP1326849B1 (de) 2008-07-16
WO2002030912A1 (en) 2002-04-18
CA2424812A1 (en) 2002-04-18
GB0025173D0 (en) 2000-11-29

Similar Documents

Publication Publication Date Title
DE60134874D1 (de) Benzodiazepin-derivate als gamma-secretase inhibitoren
DE60112055D1 (de) Inhibitoren von gamma-secretase
ATE386028T1 (de) Zyklohexylsulfone als gamma-sekretase-inhibitoren
ATE302753T1 (de) Sulfamide als gamma-secretase-inhibitoren
ATE346039T1 (de) Sulfonamido-substituierte verbrückte bicycloalkylderivative
ATE464287T1 (de) Cyclohexyl-sulphone als gamma-sekretase- inhibitoren
ATE368031T1 (de) Neue gamma secretase inhibitoren
GB0225474D0 (en) Therapeutic agents
DE60312017D1 (de) Sulfonderivate zur hemmung von gamma-secretase
DE60218458D1 (de) Isochinolinon derivate als parp inhibitoren
GB0225475D0 (en) Therapeutic agents
DE60121461D1 (de) Kondensierte pyridoindolderivate
PT998460E (pt) Novos derivados de tetrazole
DE60112306D1 (de) Kondensierte pyrazindionderivate als pde5 inhibitore
TNSN04034A1 (en) Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
ATE353217T1 (de) 3-hydroxy-6-phenylphenanthridine als pde-4 inhibitoren
ATE365735T1 (de) Cycloalkylsulfanyl-substituierte benzo böthiophene als therapeutische mittel
DE60115466D1 (de) Wirkstoffvorläufer von imidazopyridin-derivaten
DE60112960D1 (de) Kondensierte pyridoindolderivate
BG105710A (en) 5ht1 antagonists for antidepressant therapy
DE60121048D1 (de) PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE
DE60122559D1 (de) Indolderivate als pde5-inhibitoren
NZ516620A (en) 1,4-substituted 4,4-diaryl cyclohexanes
TR200100475T2 (tr) N-İkameli azabisikloheptan türevlerinin üretimleri ve kullanımları.
GB0522908D0 (en) Therapeutic agents

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties